Evidence for Stimulation of Tumor Proliferation in Cell Lines and Histotypic Cultures by Clinically Relevant Low Doses of the Galactoside-Binding Mistletoe Lectin, A Component of Proprietary Extracts

REFERENCES

• Hauser S. P. Unproven Methods in Cancer Treatment. Curr. Opinion Oncol. 1993; 5: 646–654
   PubMedGoogle Scholar
• Cassileth B. R., Chapman C. C. Alternative and Complementary Cancer Therapies. Cancer 1996; 77: 1026–1034
   PubMed Web of Science ®Google Scholar
• Eisenberg D. M., Kessler R. C., Foster C., et al. Unconventional Medicine in the United States: Prevalence, Costs, and Patterns of Use. N. Engl. J. Med. 1993; 328: 246–252
   PubMed Web of Science ®Google Scholar
• Baum M. Quack Cancer Cures or Scientific Remedies. J.R. Soc. Med. 1996; 89: 543–547
   PubMed Web of Science ®Google Scholar
• Angell M., Kassirer J. P. Alternative Medicine: The Risks of Untested and Unregulated Remedies. N. Engl. J. Med. 1998; 339: 839–841
   PubMed Web of Science ®Google Scholar
• Leroi R. Der Ätherleib zwischen Kosmos und Erde. Beiträge zu einer Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen. Freie Hochschule für Geisteswissenschaft am Goetheanum, Ed., R. Steiner Verlag, Dornach 1982; 1–10
   Google Scholar
• Gabius H-J., Gabius S. Phytotherapeutical Immunomodulation as Treatment Modality in Oncology: Lessons from Research with Mistletoe. Phytomedicines in Europe: Their Chemistry and Biological Activity, L. D. Lawson, R. Bauer. Oxford University Press, , New York 1998; 278–286
   Google Scholar
• Hauser S. P. Mistel—Wunderkraut oder Medikament?. Therapiewoche 1993; 43: 76–81
   Google Scholar
• Kleijnen J., Knipschild P. Mistletoe Treatment for Cancer. Review of Controlled Trials in Humans. Phytomedicine 1994; 1: 255–260
   PubMedGoogle Scholar
• Kaegi E. Unconventional Therapies for Cancer. 3. Iscador. Can. Med. Assoc. J. 1998; 158: 1157–1159
   PubMed Web of Science ®Google Scholar
• Gabius H-J., Gabius S., Joshi S. S., et al. From Ill-defined Extracts to the Immunomodulatory Lectin: Will There Be a Reason for Oncological Application of Mistletoe?. Planta Med. 1994; 60: 2–7
   PubMed Web of Science ®Google Scholar
• Hajto T., Hostanska K., Gabius H-J. Modulatory Potency of the β-Galactoside-Specific Lectin from Mistletoe Extract (Iscador) on the Host Defense System In Vivo in Rabbits and Patients. Cancer Res. 1989; 49: 4803–4808
   PubMed Web of Science ®Google Scholar
• Hajto T., Hostanska K., Frei K., et al. Increased Secretion of Tumor Necrosis Factor-α, Interleukin-1, and Interleukin-6 by Human Mononuclear Cells Exposed to the β-Galactoside-specific Lectin from Clinically Applied Mistletoe Extract. Cancer Res. 1990; 50: 3322–3326
   PubMed Web of Science ®Google Scholar
• Hostanska K., Hajto T., Spagnoli G. C., et al. A Plant Lectin Derived from Viscum album Induces Cytokine Gene Expression and Protein Production in Cultures of Human Peripheral Blood Mononuclear Cells. Nat. Immun. 1995; 14: 295–304
   PubMedGoogle Scholar
• Joller P. W., Menrad J. M., Schwarz T., et al. Stimulation of Cytokine Production Via a Special Standardized Mistletoe Preparation in an In Vitro Human Skin Bioassay. Arzneim-Forsch/Drug Res. 1996; 46: 649–653
   PubMed Web of Science ®Google Scholar
• Gabius H-J., Walzel H., Joshi S. S., et al. The Immunomodulatory β-Galactoside-specific Lectin from Mistletoe: Partial Sequence Analysis, Cell and Tissue Binding and Impact on Intracellular Biosignaling of Monocytic Leukemia Cells. Anticancer Res. 1992; 12: 669–676
   PubMed Web of Science ®Google Scholar
• Gupta D., Kaltner H., Dong X., et al. Comparative Cross-linking Activities of Lactose-specific Plant and Animal Lectins and a Natural Lactose-binding Immunoglobulin G Fraction from Human Serum with Asialofetuin. Glycobiology 1996; 6: 843–849
   PubMed Web of Science ®Google Scholar
• Stirpe F., Sandvig K., Olsnes S., et al. Action of Viscumin, a Toxic Lectin from Mistletoe, on Cells in Culture. J. Biol. Chem. 1982; 257: 13271–13277
   PubMed Web of Science ®Google Scholar
• Endo Y., Tsurugi K., Franz H. The Site of Action of the A-chain of Mistletoe Lectin I on Eukaryotic Ribosomes. FEBS Lett 1988; 231: 378–380
   PubMed Web of Science ®Google Scholar
• Janssen O., Scheffler A., Kabelitz D. In Vitro Effects of Mistletoe Extracts and Mistletoe Lectins. Arzneim-Forsch/Drug Res. 1993; 43: 1221–1227
   PubMed Web of Science ®Google Scholar
• Lee R. T., Gabius H-J., Lee Y. C. Ligand-binding Characteristics of the Major Mistletoe Lectin. J. Biol. Chem. 1992; 267: 23722–23727
   PubMed Web of Science ®Google Scholar
• Wu A. M., Chin L-K., Franz H., et al. Carbohydrate Specificity of the Receptor Sites of Mistletoe Toxic Lectin-I. Biochim. Biophys. Acta 1992; 1117: 232–234
   PubMed Web of Science ®Google Scholar
• Debray H., Montreuil J., Franz H. Fine Sugar Specificity of the Mistletoe (Viscum album) Lectin I. Glycoconjugate J. 1994; 11: 550–557
   PubMed Web of Science ®Google Scholar
• Galanina O. E., Kaltner H., Khraltsova L. S., et al. Further Refinement of the Description of the Ligand-binding Characteristics for the Galactoside-binding Mistletoe Lectin, a Plant Agglutinin with Immunomodulatory Potency. J. Mol. Recognit. 1997; 10: 139–147
   PubMed Web of Science ®Google Scholar
• Prehn R. T. Stimulatory Effects of Immune Reactions upon the Growths of Untransplanted Tumors. Cancer Res. 1994; 54: 908–914
   PubMed Web of Science ®Google Scholar
• Chouaib S., Asselin-Paturel C., Mami-Chouaib F., et al. The Host-Tumor Immune Conflict: From Immunosuppression to Resistance and Destruction. Immunol. 1997; 18(Today)493–497
   Google Scholar
• Elgert K. D., Alleva D. G., Mullins D. W. Tumor-induced Immune Dysfunction: The Macrophage Connection. J. Leukocyte Biol. 1998; 64: 275–290
   PubMed Web of Science ®Google Scholar
• Gabius H-J. Influence of Type of Linkage and Spacer on the Interaction of β-Galactoside-binding Proteins with Immobilized Affinity Ligands. Anal. Biochem. 1990; 189: 91–94
   PubMed Web of Science ®Google Scholar
• Kaspers B., Kaltner H., Lösch U., et al. Endotoxin-Inducible NO Synthase Activity of an Avian Macrophage Cell Line as Assay Target for Determination of the Level of Contamination of Phytopreparations. Phytomedicine 1995; 2: 133–135
   PubMed Web of Science ®Google Scholar
• Wörmann B., Anderson J. M., Liberty J. A., et al. Establishment of a Leukemic Cell Model For Studying Human Pre-B to B-Cell Differentiation. J. Immunol. 1989; 142: 110–117
   PubMed Web of Science ®Google Scholar
• Gabius S., Joshi S. S., Gabius H-J., et al. Establishment, Characterization and Determination of Cell Surface Sugar Receptor (Lectin) Expression by Neoglycoenzymes of a Human Myeloid Marker-Expressing B-lymphoblastoid Cell Line. Anticancer Res. 1991; 11: 793–800
   PubMed Web of Science ®Google Scholar
• Erdel M., Peter W., Spiess E., et al. Karyotypic Characterization of Established Cell Lines Derived From a Squamous Cell Carcinoma and an Adenocarcinoma of Human Lung Cancers. Cancer Genet. Cytogenet 1990; 49: 185–198
   Google Scholar
• Cantz M., Kresse H., Barton R. W., et al. Corrective Factors for Inborn Errors of Mucopolysaccharide Metabolism. Methods Enzymol. 1992; 28: 884–887
   Google Scholar
• André S., Unverzagt C., Kojima S., et al. Neoglycoproteins with the Synthetic Complex Biantennary Nonasaccharide or Its α2,3-/α2,6-sialylated Derivatives: Their Preparation, the Assessment of Their Ligand Properties for Purified Lectins, for Tumor Cells in Vitro and in Tissue Sections and Their Biodistribution in Tumor-bearing Mice. Bioconjugate Chem. 1997; 8: 845–855
   PubMed Web of Science ®Google Scholar
• Mosman T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxic Assay. J. Immunol. Meth. 1993; 65: 55–63
   Google Scholar
• Camby I., Salmon I., Danguy A., et al. Influence of Gastrin on Human Astrocytic Tumor Cell Proliferation. J. Natl. Cancer. Inst. 1996; 88: 594–600
   PubMed Web of Science ®Google Scholar
• Darro F., Kruczynski A., Etievant C., et al. Characterization of the Differentiation of Human Colorectal Cancer Cell Lines by Means of Voronoi Diagrams. Cytometry 1993; 14: 783–792
   PubMedGoogle Scholar
• Remmelink M., Decaestecker C., Darro F., et al. The In Vitro Influence of Eight Hormones and Growth Factors on the Proliferation of Eight Sarcoma Cell Lines. J. Cancer Res. Clin. Oncol. 1998; 124: 155–164
   PubMed Web of Science ®Google Scholar
• de Launoit Y., Kiss R., Jossa V., et al. Influences of Dihydrotestosterone, Testosterone, Estradiol, Progesterone, or Prolactin on the Cell Kinetics of Human Hyperplastic Prostatic Tissue in Organ Culture. Prostate 1998; 13: 143–153
   Google Scholar
• Janssen T., Pétein M., van Velthoven R., et al. Coregulatory Effects of Epidermal Growth Factor, Dihydrotestosterone and Prolactin on Benign Prostatic Hyperplasia Tissue Culture Proliferation. Prostate 1997; 30: 47–52
   PubMed Web of Science ®Google Scholar
• Kuttan G., Menon L. G., Kuttan R. Prevention of 20-methylcholanthrene-induced Sarcoma by a Mistletoe Extract, Iscador. Carcinogenesis 1996; 17: 1107–1109
   PubMed Web of Science ®Google Scholar
• Schumacher K. Die Problematik der sogenannten unkonventionellen Krebstherapie. Med Klinik 1986; 81: 423–428
   Google Scholar
• Berger M., Schmähl D. Studies on the Tumor-inhibiting Efficacy of Iscador in Experimental Animal Tumors. J. Cancer Res. Clin. Oncol. 1983; 105: 262–265
   PubMed Web of Science ®Google Scholar
• Fodstad O., Kvalheim G., Godal A., et al. Phase I Study of the Plant Protein Ricin. Cancer Res. 1984; 44: 862–865
   PubMed Web of Science ®Google Scholar
• Kunze E., Schulz H., Ahrens H., et al. Lack of an Antitumoral Effect of Immunomodulatory Galactoside-specific Mistletoe Lectin on N-methyl-N-nitrosourea-induced Urinary Bladder Carcinogenesis in Rats. Exp. Toxic Pathol. 1997; 49: 167–180
   PubMed Web of Science ®Google Scholar
• Kunze E., Schulz H., Gabius H.-J., bzw M.-C. Inability of Galactoside-specific Mistletoe Lectin to Inhibit N-methyl-N-nitrosourea-initiated Tumor Development in the Urinary Bladder of Rats and to Induce a Local Cellular Immune Response After Long-Term Administration. J. Cancer Res. Clin. Oncol. 1998; 124: 73–87
   PubMed Web of Science ®Google Scholar
• Kunze E., Schulz H., Adamek M., et al. Long-term Administration of Galactoside-specific Mistletoe Lectin in an Animal Model: No Protection Against N-butyl-N- (4-hydroxybutyl)-nitrosamine-induced Urinary Bladder Carcinogenesis in Rats and No Induction of a Relevant Local Cellular Immune Response. J. Cancer Res. Clin. Oncol. 2000; 126: 125–138
   PubMed Web of Science ®Google Scholar
• Heimpel H. Letter to the editor. Tumordiagn u Ther 1995; 16: 205
   Google Scholar
• Hagenah W., Dörges I., Gafumbegete E., et al. Subcutaneous Appearance of a Centrocytic Non-Hodgkins Lymphoma at the Site of Injection of a Mistletoe Preparation. Dtsch. Med. Wschr. 1998; 123: 1001–1004
   PubMed Web of Science ®Google Scholar
• Lu C., Rak J. W., Kerbel R. S. Interleukin-6 in Progression of Human Solid Tumors: Transitional Changes in the Regulation of Cell Growth, Apoptosis and Angiogenesis. Cancer J. 1997; 10: 256–261
   Web of Science ®Google Scholar
• Pattengale P. K. Role of Interleukin-6 in the Pathogenesis of Murine Plasmacytoma and Human Multiple Myeloma. Am. J. Pathol. 1997; 151: 647–649
   PubMed Web of Science ®Google Scholar
• Oshika Y., Nakamura M., Abe Y., et al. Growth Stimulation of Non-Small Cell Lung Cancer Xenografts by Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Eur. J. Cancer 1998; 34: 1958–1961
   PubMed Web of Science ®Google Scholar
• Lu C., Sheehan C., Rak J. W., et al. Endogenous Interleukin-6 Can Function as an In Vivo Growth-Stimulatory Factor for Advanced-Stage Human Melanoma Cells. Clin. Cancer Res. 1996; 2: 1417–1425
   PubMed Web of Science ®Google Scholar
• Prehn R. T., Prehn L. N. The Flip Side of Tumor Immunity. Arch. Surg. 1989; 124: 102–106
   PubMed Web of Science ®Google Scholar
• Kim Y. J., Borsig L., Varki N. M., et al. P-selectin Deficiency Attenuates Tumor Growth and Metastasis. Proc. Natl. Acad. Sci. USA 1998; 95: 9325–9330
   PubMed Web of Science ®Google Scholar
• Villalobo A., Gabius H.-J., bzw M.-C. Signaling Pathways for Transduction of the Initial Message of the Glycocode into Cellular Responses. Acta Anat. 1998; 161: 110–129
   PubMedGoogle Scholar
• Costes V., Liautard H.-J., bzw M.-C., Picot M-C., et al. Expression of the Interleukin-6 Receptor in Primary Renal Cell Carcinoma. J. Clin. Pathol. 1997; 50: 835–840
   PubMed Web of Science ®Google Scholar